The Enzyme That Went Rogue: Inside the Shocking Link Between Your Pancreas and a Hidden Cellular Switch
New research in Signal Transduction and Targeted Therapy reveals how the METTL3 enzyme drives pancreatic cancer, offering a revolutionary new therapeutic target
By Foodie Pundit Newsroom - Published - Updated - Section: Food Safety
Key points
- A cellular enzyme called METTL3, when overactive in the pancreas, is a key driver of aggressive pancreatic acinar cell carcinoma (ACC).
- METTL3 promotes cancer growth by chemically modifying RNA related to cell cycle genes and by creating a supportive tumor microenvironment.
- The cancer's survival is dependent on METTL3, as genetically deleting the enzyme or blocking it with a drug (STM2457) caused rapid tumor cell death in mouse models.
- This research establishes METTL3 as a highly promising therapeutic target for a cancer that currently has few effective treatment options.
- The study highlights the importance of the epitranscriptome (RNA modifications) as a new frontier for developing targeted cancer therapies.
This report is part of Foodie Pundit premium coverage. Foodie Pundit members read the full story. See membership.
Sources and methodology
Reported from primary records. Open any source to verify a claim.
More from the Foodie Pundit Newsroom
- Grocery Giants Albertsons and Safeway Fail to Block 14 Years of Opioid Claims in Washington State Lawsuit
- Smart farming tames food prices, boosts green cred for restaurants
- Clinical Study Validates GI Side Effects of Popular Weight Loss Medications
- Mexican Gastronomy Drives Regional Economies and Global Dining Shifts
- SF dining flexes, adapts to survive modern hellscape